AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Tresiba (Novo Nordisk) (tresiba.com)
This is a high-substance, low-BS site driven by stringent pharmaceutical regulatory requirements. It prioritizes safety documentation and technical dosing data over marketing hyperbole.
To further reduce the BS score, the site should update the MMIT formulary data which is currently over 24 months old. They should replace the emotive hero heading Find your reason with a more outcome-oriented metric. Finally, adding inline citations for the powerful A1C reduction claim would bridge the small gap between marketing and clinical proof.
The site exhibits high substance-to-fluff ratios, specifically in the detailed dosing instructions and molecular explanations. Specific nouns and technical specifications like 100 Units per mL and 200 Units per mL concentrations and the 8-hour minimum interval between doses provide high density. Some points were lost for repetitive value propositions regarding 24-hour management and the emotive hero heading Find your reason for managing your blood sugar which lacks a specific metric.
If your content is buried under div based wrappers, AI will treat it as noise instead of meaning. Check your Machine Readability Index with a free one page structural interpretation.
There is virtually zero semantic drift between the homepage signal and sub-page delivery. The homepage H1 focuses on Safety Information, which is meticulously detailed across all sub-pages, and the hero promise of long-acting insulin is technically substantiated on the About Tresiba page through the string of pearls molecular design explanation. Messaging remains consistent for both adults and pediatric patients over 1 year of age across the entire sitemap.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site avoids trust theatre entirely, with a review_count of 0 and no unverified patient testimonials. Trust is established through high-authority proof paths, including direct links to FDA MedWatch and the full Prescribing Information PDF. A minor penalty of 1 point was applied in the Trust and Proof pillar because the formulary data mentioned on the Savings page is dated February 2024, which is 28 months stale relative to the June 2026 system date.
The proof density is high, featuring specific regulatory-required evidence such as the 100 U per mL and 200 U per mL concentrations and step-by-step instructions for the FlexTouch pen. Verifiable evidence outweighs vague assertions, with only a few marketing phrases like powerful reduction lacking an immediate inline clinical citation, though they are supported by the linked PI.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
While the site uses industry clichés such as powerful A1C reduction and works the way the body’s insulin does, these are largely regulatory-approved descriptions rather than empty marketing. The commodity fingerprint is reduced by the specific molecular differentiation of insulin degludec. However, template sections like Support and Resources and the use of actor portrayal labels are standard pharma boilerplate.
Authority is robustly supported by the schema_json, which correctly identifies the page as a MedicalWebPage with Drug and MedicalCondition properties. The manufacturer, Novo Nordisk, is clearly identified with links to its affordability programs at NovoCare.com. No individual experts are named, but the authority is deferred to the FDA and healthcare providers, which is standard and credible for this industry.
There is no disconnect between marketing tone and clinical demonstration. Claims of around-the-clock management are backed by technical descriptions of how the insulin releases slow and steady from its molecular chain. The site does not over-promise; it balances every efficacy claim with a corresponding safety warning as required by law.
Medical Devices, Pharma & Biotech BS: Tresiba (Novo Nordisk) (tresiba.com)
The site perfectly aligns with the Pharma and Biotech category, utilizing mandatory regulatory frameworks and clinical terminology. The presence of comprehensive Important Safety Information (ISI) and Prescribing Information (PI) links confirms its status as a highly regulated medical product site.
A page that loads perfectly for users can still return an empty shell to an AI crawler. Examine the Crawlability Technical Guide and understand why script free extraction is the real measure of visibility.
“The score of 15 is exceptionally low, driven primarily by the high information density and lack of semantic drift. The few points accrued came from aging formulary data in the Trust pillar and standard industry clichés in the Commodity Fingerprint pillar. The site serves as a benchmark for substance in a regulated industry.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 20, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Tresiba (Novo Nordisk) to view the most current version of their content and see directly what the company offers.